izpis_h1_title_alt

Plasma extracellular vesicle characteristics correlate with tumor differentiation and predict overall survival in patients with pancreatic ductal adenocarcinoma undergoing surgery with curative intent
ID Badovinac, David (Avtor), ID Goričar, Katja (Avtor), ID Zavrtanik, Hana (Avtor), ID Petrič, Miha (Avtor), ID Lavrin, Teja (Avtor), ID Mavec, Nina (Avtor), ID Dolžan, Vita (Avtor), ID Tomažič, Aleš (Avtor), ID Lenassi, Metka (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (919,43 KB)
MD5: 7BA76BC225EBC111F81D81AA1310C9BB
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2075-4426/11/2/77 Povezava se odpre v novem oknu

Izvleček
Better preoperative characterization of patients with pancreatic ductal adenocarcinoma (PDAC) would aid in treatment optimization. Extracellular vesicles (EV) are promising, largely unexplored biomarkers in PDAC. This study aimed to evaluate if plasma EV characteristics are associated with PDAC clinical characteristics and overall survival (OS). The prospective cohort included 34 PDAC patients undergoing surgery with curative intent. Patient data and plasma samples were collected preoperatively, intraoperatively and one month postoperatively. Small plasma EV (sEV) concentration and size were determined by nanoparticle-tracking analysis. A Mann-Whitney test, Spearman's rho and Cox regression were used in statistical analysis. Preoperatively, patients with poorly differentiated tumors had significantly larger plasma sEVs when compared to patients with well/moderately differentiated tumors (mean diameter 176.9 vs. 149.2 nm, p = 0.021), the sEV size even enabling discrimination of the two groups (AUC = 0.742, 95% CI = 0.560-0.923). Plasma sEV characteristics were also a predictor of OS in multivariable analysis. Patients with a more than 33.8% increase in sEV concentration after one month had 7.2 months shorter median OS (p = 0.002), while patients with a more than 28.0% decrease in sEV size had 9.2 months shorter median OS (p = 0.045). Plasma sEV concentration and size correlate with tumor differentiation and may predict OS in PDAC patients. In the future, plasma sEV characteristics could contribute to improved patient stratification for optimized treatment.

Jezik:Angleški jezik
Ključne besede:pancreatic cancer, tumor differentiation, overall survival, extracellular vesicles, nanoparticle-tracking analysis, plasma biomarkers, liquid biopsy
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2021
Št. strani:12 str.
Številčenje:Vol. 11, iss. 2, art. 77
PID:20.500.12556/RUL-134776 Povezava se odpre v novem oknu
UDK:616-006
ISSN pri članku:2075-4426
DOI:10.3390/jpm11020077 Povezava se odpre v novem oknu
COBISS.SI-ID:49258243 Povezava se odpre v novem oknu
Datum objave v RUL:01.02.2022
Število ogledov:8113
Število prenosov:163
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Journal of personalized medicine
Skrajšan naslov:J. pers. med.
Založnik:MDPI
ISSN:2075-4426
COBISS.SI-ID:31207641 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:01.02.2021

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:rak trebušne slinavke, diferenciacija tumorja, splošno preživetje

Projekti

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P1-0170
Naslov:Molekulski mehanizmi uravnavanja celičnih procesov v povezavi z nekaterimi boleznimi pri človeku

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:J3-9255
Naslov:Ovrednotenje Nef-vsebujočih zunajceličnih veziklov v plazmi kot biooznačevalca aktivnega rezervoarja virusa HIV-1 pri aviremičnih posameznikih

Financer:Drugi - Drug financer ali več financerjev
Program financ.:University Medical Centre Ljubljana
Številka projekta:20150180

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj